Glaucoma Insights

Pharmaceutical company files IND application with FDA for glaucoma candidate

September 08, 2021

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

Study highlights favorable two-year outcomes of standalone use of surgical system on mild to moderate open-angle glaucoma

August 24, 2021

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.

Study: Gene therapy could preserve vision in patients with retinal disease, serious retinal injury

July 28, 2021

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

FDA grants Investigational Device Exemption for MINIject in glaucoma patients

July 15, 2021

According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.

Studying glaucoma epidemiology at the center of the Earth

January 30, 2021

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.

Effect of Open-Angle Glaucoma Medications on Ocular Surface

February 17, 2020

MIGS Surgery to Manage Non-Adherence in Open-Angle Glaucoma

February 10, 2020

Importance of Adherence in Treatment of Open-Angle Glaucoma

February 10, 2020

Targeting MMP to Treat Open-Angle Glaucoma

February 03, 2020

Emerging Therapy for Open-Angle Glaucoma

February 03, 2020